EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

Talha Munir, Peter Hillmen

New England Journal of Medicine · 2024

DOI: 10.1056/nejmc2402472 ↗

Kurz gefasst

Leserbrief in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Talha Munir und 1 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Cancer Centre, Leeds, United Kingdom peter.hillmen@nhs.net. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellNeoplasm, ResidualAntineoplastic Combined Chemotherapy ProtocolsHumansRandomized Controlled Trials as TopicCyclophosphamideRituximabSurvival AnalysisAdeninePiperidinesSulfonamidesBridged Bicyclo Compounds, HeterocyclicVidarabine

Substanzen

CyclophosphamideRituximabibrutinibAdeninePiperidinesvenetoclaxSulfonamidesBridged Bicyclo Compounds, HeterocyclicfludarabineVidarabine

Autor:innen und Institutionen

  • Leeds Cancer Centre, Leeds, United Kingdom peter.hillmen@nhs.net.

Zitieren

APA

Munir, T., & Hillmen, P. (2024). Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmc2402472

Vancouver

Munir T, Hillmen P. Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine. 2024. doi:10.1056/nejmc2402472

BibTeX
@article{Munir2024,
  author = {Munir, Talha and Hillmen, Peter},
  title = {Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease},
  journal = {New England Journal of Medicine},
  year = {2024},
  doi = {10.1056/nejmc2402472}
}
Kostenlos starten →